Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,004.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price cut by Truist Financial from $1,126.00 to $1,004.00 in a research note published on Wednesday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other analysts have also recently weighed in on REGN. BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Barclays lowered their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. Finally, Wolfe Research started coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective for the company. One research analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $1,037.33.

Regeneron Pharmaceuticals Trading Down 5.0 %

Shares of REGN stock opened at $696.88 on Wednesday. Regeneron Pharmaceuticals has a fifty-two week low of $691.00 and a fifty-two week high of $1,211.20. The company has a 50 day moving average price of $751.44 and a 200 day moving average price of $962.58. The stock has a market capitalization of $76.58 billion, a P/E ratio of 17.25, a price-to-earnings-growth ratio of 2.19 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Sachetta LLC increased its holdings in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares in the last quarter. Rakuten Securities Inc. raised its position in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $26,000. Fairfield Financial Advisors LTD acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $37,000. Finally, Ashton Thomas Private Wealth LLC purchased a new position in Regeneron Pharmaceuticals during the second quarter worth $39,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.